収穫適期幅が長く安定多収なさとうきび新品種「NiTn20」の育成

A new sugarcane cultivar "NiTn20" developed by the National Agricultural Research Center for Kyushu Okinawa Region, Nishinoomote, Kagoshima, Japan, was originated from a cross of NiF4 X NiF5 made in 1991. It was chosen from 827 seedlings through four selection steps and eight yield evaluations including a regional adaptability test, for a total of 13 years. After following the breeding programs, It was officially registered as "NiTn20" (Sugarcane Nourin 20), by the Ministry of Agriculture Forestry and Fisheries of Japan in 2005. The main characteristics of "NiTn20" are as follows. Stem length : Greater than NiF8 and Ni9. Stem diameter : Slightly less than NiF8. Early stage growth : Good germination ; good and fast stem elongation. Tillering ability : Better than NiF8. Maturity class : Earlier than NiF8. Sugar yield : More than NiF8 for spring planting and ratooning. Related milling characteristics : Same as NiF8, excluding the fiber. Juice quality characteristics : Rich in sucrose. Sucrose reducing level at post harvest is equal to that of NCo310. "NiTn20" adapted to the Yaeyama region and the southern part of Okinawa Island with it\u27s high yield and high sucrose content with early maturity, and was adopted as a recommended cultivar in Okinawa Prefecture「NiTn20」 (旧系統名「KF92T-519」) は九州沖縄農業研究センターにおいて育成された, 収穫適期幅が長く安定多収なさとうきび新品種である。安定した収量と早期高糖性を具える品種を育成するために, 種子親として, 糖度上昇が早く, 茎揃いの良い「NiF 4」を, 花粉親として, 発芽, 萌芽, 初期生育が優れ, 分げつ性が強く黒穂病抵抗性の茎数型多収品種「NiF 5」を選定し, 交配を行った。得られた種子から実生を養成し, 実生選抜, 4回の栄養系選抜, 系統適応性検定試験, 特性検定試験, 奨励品種決定調査を経て育成した。2004年に沖縄県の奨励品種として採用され, 2005年に「さとうきび農林20号」として命名登録された。発芽は「NiF 8」と同程度に良く, 萌芽は「NiF 8」, 「Ni 9」よりも優れる "極良" である。分げつ性は「NiF 8」よりも優れる "やや強" である。原料茎数は春植えで「NiF 8」より多く, 株出しでは「NiF 8」, 「Ni 9」より多い。沖縄県八重山地域および沖縄本島南部地域において, 春植え, 株出しともに, 「NiF 8」, 「Ni 9」よりも原料茎重, 可製糖量が多い。株出しで発生の多い黒穂病に対する抵抗性は "強" である。早期高糖性で, 12月収穫では「NiF 8」よりも高糖多収である。また, 生育初期から茎の伸びが良く, 既存品種の収量が少ない圃場 (島尻マージ土壌) でも比較的多収である。黒穂病汚染地域が多く, 通常の年は12月に収穫が行われている沖縄県八重山地域および沖縄本島南部地域に普及する見込みである

Comparative double-blind trial of KN-7 tablet and Robaveron injection in the treatment of neurogenic bladder

37施設で, 神経因性膀胱233例を対象に, ロバベロン注射剤を標準薬とし, KN-7錠剤の経口投与による排尿障害に対する有用性を, 二重盲検群間比較試験で比較検討した.解析対象例はKN-7群108例, ロバベロン群107例である.KN-7群は1日6錠投与した.改善度の効果判定では改善以上K群40.7%, R群38.7%, やゝ改善以上それぞれ76.9%, 72.6%と有意差はなかった.臨床所見中改善の良かった項目は, 尿意, 残尿感, 尿失禁, 排尿までの時間, 排尿時間, 尿勢-排尿力と尿線中断の改善などで, これらの改善以上はK群35.8%, R群30.8%で, 有意差はなかった.副作用はK群0.9%, R群6.8%, K群が有意に少なかった.両剤とも主として下痢で, R群ではその他頭痛, 頻脈, 肝機能障害, 発熱感などを少数例認めた.臨床検査値ではGOT, GPTの上昇が2例あった.有用度有用以上はK群46.3%, R群45.8%で有意差はなかった.疾患別では, 末梢神経疾患, 膀胱の性状では弛緩性, 時期では12ヵ月以内の例で特に改善率が高かった.以上から, KN-7錠剤は, ロバベロン注射剤に比べ, 同等の効果が期待でき, 安全性も高く, 長期投与あるいは外来患者の治療にも適するThe clinical effectiveness, safety and usefulness of KN-7 tablet as a new oral application of the prostatic extract, on urinary dysfunction of neurogenic bladder were compared with those of Robaveron injection by the double-blind test method. In the study, 2 tablets t.i.d. and a shot of intramuscular injection 1 ml a day were given successively for 3 weeks. A total of 233 cases were reported from 37 facilities belonging to the KN-7 Clinical Research Group. Some of them were excluded or dropped out. The number of cases used for analysing the effectiveness, safety and usefulness were 214, 232 and 215, respectively. There was no bias between the two groups with a significant homogeneity in the background. In the overall clinical effectiveness, the effective rate including excellent, moderate and slightly effective was 76.9% with KN-7 and 77.4% with Robaveron. In the clinical usefulness, the rate of usefulness of slightly useful or above was 75.0% with KN-7 and 75.7% with Robaveron. There was no significant difference between the two groups in the clinical effective and useful rates at a significant level of 5%. Side effects were observed in 1 of the 114 (0.9%) patients given KN-7 and 8 of the 118 (6.8%) patients given Robaveron. The incidence of adverse reactions with KN-7 was significantly lower than that with Robaveron. Based on the results, it was concluded that KN-7 tablets, 2 tablets t.i.d., would be as effective and useful as a Robaveron injection 1 ml daily and safer than the latter in the treatment of neurogenic bladder